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Abstract
Context—Current drug treatments for schizophrenia are inadequate for many patients and,
despite five decades of drug discovery, all use the same mechanism-dopamine D2 receptor
blockade. Understanding the pathophysiology of the disorder is thus likely to be critical to the
rational development of new treatments for schizophrenia.
Objective—To investigate the nature of the dopaminergic dysfunction in schizophrenia using
meta-analysis of in vivo studies.
Data sources—The MEDLINE, EMBASE and PsychINFO databases were searched for studies
from January 1, 1960, to July 1, 2011.
Study selection—Forty-four studies were identified that compared in vivo striatal dopaminergic
function in 618 patients with schizophrenia with 606 controls using positron emission tomography
or single photon emission computed tomography.
Data extraction—Demographic, clinical and imaging variables were extracted from each study
and effect sizes determined for the measures of dopaminergic function. Studies were grouped into
those of presynaptic function, and dopamine transporter and receptor availability. Sensitivity
analyses were conducted to explore the consistency of effects and the effect of clinical and
imaging variables.
Data synthesis—There was a highly significant elevation (p<0.0001) in presynaptic
dopaminergic function in schizophrenia with a large effect size (Cohen’s d=0.79). There was no
evidence of alterations in dopamine transporter availability. There was a small elevation in D2/3
receptor availability (Cohen’s d=0.26), but this was not evident in drug-naïve patients and was
influenced by the imaging approach used.
Conclusions—The locus of the largest dopaminergic abnormality in schizophrenia is
presynaptic-affecting dopamine synthesis capacity, baseline synaptic dopamine levels and
dopamine release. Current drug treatments - which primarily act at D2/3 receptors - fail to target
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these abnormalities. Future drug development should focus on the control of presynaptic
dopamine synthesis and release capacity.
Introduction
Schizophrenia remains one of the leading causes of global disease burden in adults despite
over fifty years of drug development.1 Understanding its neurobiology is critical for future
rational drug discovery.2, 3 The dopamine hypothesis of schizophrenia was first proposed
over thirty years ago on the basis of indirect evidence. It received support from studies of
post-mortem brain tissue that found increased striatal D2/3 receptor density and dopamine
levels in schizophrenia and from studies of CSF dopamine and its metabolites (see 4-6 and
reviews7, 8). However post-mortem studies are not able to measure some aspects of the
dopaminergic function, such as dopamine release, and are potentially biased by the effects of
antipsychotic treatment and agonal events, whilst the CSF studies were inconsistent and
unable to provide insights into the regional aspects of dopamine dysfunction.9-11 The
introduction of positron emission tomography (PET) and single photon emission computed
tomography (SPECT) imaging enabled the investigation of in vivo cerebral dopamine
neurotransmission free of these limitations.11-13
PET and SPECT imaging has been used to investigate dopaminergic parameters in
schizophrenia, beginning with studies of D2/3 receptors14, 15 and later covering presynaptic
function, including dopamine synthesis capacity and dopamine release, and transporters16-19
(see supplementary materials for further background on these approaches). To our
knowledge there has not been a previous meta-analysis of the presynaptic or dopamine
transporter findings in schizophrenia, and, since the previous D2/3 meta-analysis in drug
free/naive patients20, there have been a large number of new studies which approximately
doubles the sample size.
The purpose of our meta-analysis is to synthesise the PET and SPECT imaging findings on
dopaminergic function in schizophrenia, and to consider their implications for the treatment
of schizophrenia. We focus on the striatum because this has the highest density of dopamine
projections in the brain21, and dopaminergic dysfunction here can be reliably imaged and
has been linked to the severity of symptoms, response to treatment and the onset of the
disorder.22-25 We group findings into studies of presynaptic dopaminergic function
(dopamine synthesis capacity, dopamine release and synaptic dopamine levels), dopamine
transporter and dopamine receptor availability. The studies of dopamine synthesis capacity
are grouped with those of dopamine release and synaptic dopamine levels (which use
pharmacological challenges that either deplete or release dopamine from presynaptic
terminals) because animal 26-28 and in vivo human evidence 29 indicates that they index
related aspects of dopaminergic function. However, the results are also given separately for
these different methodological approaches for comparison.
Researchers can view the study data and add future studies on our open-access database and
wiki (http://www.schizophreniadatabase.kcl.ac.uk).
Methods
Data sources and study selection
The entire PubMed, PsychINFO and MEDLINE electronic databases were searched from 1st
January 1960 up to 1st July 2011. To be included in the meta-analysis a paper needed to
report in vivo PET or SPECT imaging findings on striatal dopaminergic function in patients
with schizophrenia and a control group, including the mean and standard deviations for both
groups. Current antipsychotic treatment was an exclusion criterion for the studies of
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dopamine receptors, because this affects dopamine receptor binding potential.30 See
supplementary figure 1 for search results and supplementary materials for further details on
the search and inclusion/exclusion criteria.
Data extraction
The main outcome measure was the difference in the dopaminergic imaging parameter
between healthy controls and patients with schizophrenia.
The following additional information was extracted from all the studies: authors, year of
publication, population characteristics of the control and patient groups (group size, age,
gender, antipsychotic use, diagnosis, symptom ratings), characteristics of the PET or SPECT
imaging (radiotracer, other methodological factors reported), scanner characteristics
(scanner type and resolution), and modeling method.
Data analysis
Separate meta-analyses were conducted for the studies of presynaptic dopaminergic
function, dopamine receptors and dopamine transporters. The standardized effect sizes of the
individual studies were entered in a random-effects meta-analytic model.31, 32 The summary
effect sizes (Cohen’s d) were computed using a restricted maximum-likelihood estimator.33
Publication bias was assessed using funnel plots. Heterogeneity was assessed by calculating
the I2 value (I2 values <50% indicate low-moderate heterogeneity whilst values >50%
indicate moderate-high heterogeneity).34 Leave-one-out sensitivity analyses were
conducted. Sources of bias and heterogeneity were evaluated using meta-regression (for
publication year and age) and sub-group analyses (for antipsychotic treatment, illness
duration and imaging approach). A significance level of p<0.05 (two-tailed) was used for all
analyses. See supplementary materials for further methodological details.
Results
Pre-synaptic dopaminergic function
Seventeen studies described in fifteen publications (three reported in one paper25) met
inclusion criteria. We excluded one of our papers35 from the main analysis because it reports
additional data on the same subjects included in a previous report36, although the data are
used in sub-analyses where there is no subject duplication, and another paper because the
comparator group was siblings.37 Overall the studies include a total of 231 patients and 251
controls. Study details are reported in supplementary tables 1 and 2.
There was a significant elevation in schizophrenia, with a summary effect size of d=0.79
(figure 1, 95%-CI: 0.52 to 1.07, z=5.65, p<0.0001).
Heterogeneity and sensitivity analyses
The I2 value was 39.92% (95%-CI for I2: 0 to 77.03 %), indicating low to moderate
heterogeneity between studies. Whilst the regression test for funnel-plot asymmetry was not
significant (z=1.52, p=0.13), visual inspection of the funnel-plot suggested asymmetry,
indicating possible publication bias. The trim-and-fill analysis indicated 3 potentially
missing studies on the left side of the funnel-plot (all with large standard errors and small
effect sizes, see supplementary figure 2). Nevertheless, the summary effect size remained
large and highly significant after correcting for these putatively missing studies (corrected
effect size: d=0.67; z=4.55, p<0.0001, 95%-CI: 0.37 to 0.94, I2=48.83%, 95%-CI of I2:
10.17 to 81.01%).
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The summary effect size reached significance in all cases in the leave-one-out analysis, with
summary effect sizes varying from d=0.73 to d=0.86 (all p<0.0001).
Meta-regression indicated there was no influence of the year of publication (β=−0.02,
F1,13=0.99, p=0.34), or subject age (β=0.004, F1,12=0.015, p=0.90). In case current
antipsychotic drug treatment was confounding the results, the meta-analysis was rerun
exclusively for studies of drug-free/drug-naïve patients. This showed a significant elevation
in drug free/drug naïve patients compared to controls (n=13, d=0.69; 95%-CI: 0.36 to 1.01,
z=4.14, p<0.0001, I2=46.46%, 95%-CI for I2: 0 to 85.31%). The effect sizes for the studies
grouped by antipsychotic treatment are shown in figure 2.
The effect sizes grouped by imaging method are shown in supplementary figure 3. There
was a significant elevation in schizophrenia when the meta-analysis was restricted to the
studies using radiolabeled-DOPA (n=11; d=0.78; 95%-CI: 0.38 to 1.18, z=3.82, p=0.0001,
I2=52.62%, 95%-CI for I2: 3.19 to 84.02%). The effect sizes were similarly positive in the
studies of dopamine release (d=1.35, d=0.88, and, for the Laruelle et al, 1999 report
combining 3 cohorts: d=0.91) and in the studies of synaptic dopamine levels (d=1.09 and
d=0.61), but there were too few studies to rerun the meta-analysis separately for these
approaches.
Dopamine transporter
Eleven studies met inclusion criteria, providing data on a total of 152 patients and 132
healthy controls. Study details are shown in supplementary tables 3 and 4.
There was no evidence of a significant difference between patients with schizophrenia and
controls (figure 3, d=−0.34, 95%-CI: −0.75 to +0.07, z=−1.64, p=0.10).
Heterogeneity and sensitivity analyses
The I2 value was 64.04% (95%-CI of I2: 25.22 to 88.99 %), indicating moderate-large
heterogeneity between studies. There was no evidence for publication bias (regression test
for funnel plot asymmetry: z=−1.75, p=0.08; no missing studies estimated by trim-and-fill
analysis; see supplementary figure 4 for the funnel-plot), and no significant effect of year of
publication (β=−0.01, F1,9=0.04, p=0.85), or age (β=0.02, F1,9=0.25, p=0.63) on the effect
size. The sub-group analyses found no group differences (see supplementary materials).
Dopamine receptors
D2/3 receptors—Twenty-two studies met inclusion criteria, providing data on 337
patients and 324 healthy controls (nb: data from15 form part of a subsequent larger data-
set38). The population characteristics and methodological details of the studies are shown in
supplementary tables 5 and 6.
There was a significant elevation in schizophrenia with a summary effect size of d=0.26
(figure 4, 95%-CI: 0.001 to 0.52, z=1.97, p=0.049).
Heterogeneity and sensitivity analyses—The I2 value was 63.93% (95%-CI of I2:
39.65-84.81%), indicating moderate-large heterogeneity between studies. There was no
evidence for publication bias (regression test for funnel plot asymmetry: z=1.32, p=0.19; no
missing studies estimated by trim-and-fill analysis; see supplementary figure 5 for the
funnel-plot), and no significant effect of year of publication (β=−0.03, F1,19=2.27, p=0.15)
or age (β=0.01, F1,18=0.34, p=0.57) on the effect size.
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In the leave-one-out analysis the effect sizes varied from d=0.18 to d=0.32 (with p-values
from p=0.11 to p=0.01 respectively), and were not significant on 14 of the 22 iterations. We
repeated the meta-analysis including one study39 initially excluded due to the relatively
short antipsychotic drug wash-out period and found a non-significant effect size of d=0.25
(95%-CI: −0.01-0.51, z=1.8753, p=0.061, I2=62.75%, 95%-CI of I2: 38.65-84.13%). The
sub-group analyses identified no significant difference between patients and controls in
studies exclusively of antipsychotic-naïve patients or that used benzamide radiotracers,
whilst significant differences were found in studies including patients who had received
prior antipsychotic treatment or that used butyrophenone radiotracers (see supplementary
materials for these analyses and comparisons of illness duration between sub-groups).
Other dopamine receptors—We identified four studies of D1 receptor availability in
untreated patients40-43- too few to permit meta-analysis. None of these found a significant
difference in striatal D1 availability between patients with schizophrenia and controls,
although one study43 found a trend towards an increase in antipsychotic-naïve but not drug-
free patients (see supplementary materials for overview).
Striatal sub-regions
We repeated the meta-analyses for the caudate and putamen separately. In the studies of
presynaptic function, there was a significant elevation in schizophrenia for the putamen (8
studies, d=0.51, z=2.72, p=0.007, 95%-CI: 0.14-0.88) but not the caudate. There were no
significant differences in the caudate or putamen between patients and controls in the studies
of dopamine transporter or D2/3 receptor availability (see supplementary materials for
details).
Discussion
The main findings from our meta-analyses are that presynaptic dopaminergic function is
altered in schizophrenia, with a large effect size (d=0.79), whilst there is no difference in
dopamine transporter availability and a small elevation in D2/3 receptor availability,
although the latter was not consistent. These findings are summarised schematically in
figure 5.
Methodological considerations
One methodological consideration common to all meta-analyses is that they are limited by
the quality of the studies that are included. We have included all relevant studies rather than
applying quality screening as this may introduce other biases, although this involves pooling
findings from studies using different radiotracers, scanners, data collection, and methods of
pharmacokinetic analysis. We have summarised these variables (supplementary tables 1-6)
to enable readers to make judgements about individual studies. Whilst including all studies
has the advantage of reducing selection biases and increasing the generalizability of
findings, there is a risk of diluting effects.
There was low-moderate heterogeneity in the studies of presynaptic dopaminergic function,
suggesting that there is consistency across studies. However there was moderate to large
heterogeneity in the studies of dopamine transporter and D2/3 receptor availability. Potential
sources for this were evaluated in secondary analyses and are discussed below.
Nevertheless, as the random effects model used in the meta-analyses does not assume
homogeneity of effects, our findings should be robust to heterogeneity.
Presynaptic dopaminergic function—Whilst the trim-and-fill analysis indicated there
may be missing studies, the elevation in patients remained large and highly significant after
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correcting for putatively missing studies. There was a highly significant and large effect size
in all the iterations of the leave-one-out analysis, indicating that the elevation in presynaptic
dopaminergic function was not dependent on the inclusion of any one study. We found a
large positive effect size when the meta-analysis was restricted to studies using radio-
labelled DOPA, and, although there were insufficient studies to permit separate meta-
analyses, there were similar positive effect sizes in the studies that used AMPT or
amphetamine challenges, suggesting the elevation is consistent across technique. The
elevation was evident when studies of patients currently taking antipsychotic treatment were
excluded from the meta-analysis, indicating that antipsychotic treatment is unlikely to
explain the effect. We cannot, however, exclude the possibility that prior treatment had a
persisting effect in the studies of drug free patients; although figure 2 indicates that in
absolute terms the effect sizes were at least as great in the studies of drug naïve patients as in
patients who had received prior treatment, suggesting that this is not the case.
The radiolabeled-DOPA studies used several different analytic and imaging methods,
including the simple ratio approach which does not account for many of the complexities of
radiolabeled-DOPA analysis, and is highly dependent on scanning duration44- factors that
may contribute to the negative effect size in the only study to use this approach.45
Nevertheless, that the elevation in schizophrenia was evident across studies using a variety
of methods and analytic approaches suggests it is robust.
The elevation in presynaptic dopaminergic function could be due to an increased density of
dopamine terminals in the striatum. However, this interpretation is unlikely for two reasons:
first, there is no evidence of a similar elevation in dopamine transporter availability in our
meta-analysis or in the vesicular monoamine transporter (both in vivo markers of dopamine
neuron terminal density)46, 47, and, second, dopamine neuron numbers are not elevated in
post-mortem samples.48 This thus indicates that the increased dopamine synthesis capacity
and dopamine release reflects functional changes rather than increased neuronal density.
Whilst elevated dopamine synthesis capacity could reflect increased enzyme activity in
compensation for reduced L-DOPA or dopamine levels, this interpretation is not consistent
with the evidence that synaptic dopamine levels and dopamine release respectively are also
increased and positively correlated.35 Together the presynaptic studies thus suggest there is
increased dopaminergic activity reflected in increased dopamine synthesis capacity, and
dopamine release.35 This is consistent with evidence of increased turnover of striatal
dopamine in schizophrenia.49 Further work is needed to determine if dopamine synthesis
capacity is related to dopamine release in schizophrenia, as has been found for synaptic
dopamine and dopamine release,35 and if other aspects of dopaminergic function (eg:
conversion of tyrosine to L-DOPA, and dopamine catabolism) are also abnormal.
Dopamine transporter availability—There was no evidence of publication bias.
Antipsychotic treatment is unlikely to explain our finding because most of the patients in the
dopamine transporter studies were drug-naive, and the lack of difference between patients
and controls was also evident when the studies of treated patients were excluded. A likely
source of the heterogeneity between studies is the number of different radiotracer imaging
approaches used, although we were not able to formally assess this. Differences in clinical
characteristics, such as variation in the severity and phase of illness and drug free intervals,
are evident between studies (see supplementary tables) and may be a further source of
heterogeneity between studies.
Dopamine receptor availability—There was no evidence of publication bias. There was
no significant difference between patients and controls on fourteen of the twenty-two
iterations of the leave-one-out analysis, indicating that the finding of a difference in the
meta-analysis is not robust. In the sensitivity analyses we could not detect a difference
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between patients and controls when the meta-analysis was restricted to purely drug-naive
patients, or when it was restricted to patients who had received prior treatment scanned with
benzamide radiotracers. The two studies that used ergot radiotracers included a mixture of
drug-naïve and prior treated patients and found no difference between patients and controls,
in line with the findings with benzamide radiotracers. However, when the meta-analysis was
restricted to butyrophenone radiotracers there was an elevation in patients. Interestingly this
was not evident in the one butyrophenone study exclusively of drug-naïve patients. These
further analyses thus suggest that the imaging approach used and the inclusion of patients
who had received prior antipsychotic treatment are likely to contribute to the inconsistency
in the meta-analysis. Other differences in clinical characteristics may also contribute to this-
in particular: duration of illness (which was shorter in the drug-naive patients), whether
illness duration included the prodrome, and the nature and severity of symptoms (see
supplementary table 6).
There are differences in the pharmacokinetic properties of the different radiotracers, and the
analytic methods used to characterise them, as well as their pharmacodynamic
characteristics50-52, so it is not possible to disentangle which of these factors might underlie
the effect of imaging approach on our findings. For example, in comparison with the
benzamide radiotracer raclopride, in membrane, slice and cell preparations the
butyrophenone radiotracers NMSP and spiperone have shown paradoxical binding decreases
following dopamine depletion53, 54 and either increases or no overall change following
stimulated release53-55. Some55 though not all studies56 have found that spiperone has a
greater tendency to bind to internalized receptors than does raclopride. NMSP and spiperone
also have higher affinity for D2/3 receptors than raclopride (Kd values in the picomolar
range compared to the nanomolar range for raclopride) and have slower kinetics50, which
make it more difficult to obtain quantitative estimates from short-duration PET studies and
necessitates the use of a different kinetic model for analysis.15, 57
When evaluating the sensitivity analyses it is also important to consider that the risk of type-
II errors is increased when the number of studies is reduced, and there is an inevitable
decrease in the precision of the estimate. This is reflected in the wide confidence intervals
for the drug-naive and drug-free groupings, and therefore the finding of a lack of a
significant difference in the drug-naive studies needs to be seen in the context of the reduced
power to find such a difference. Finally elevated baseline synaptic dopamine in
schizophrenia could potentially make group differences harder to detect. Nevertheless,
overall one can conclude that whilst there was a small elevation in D2/3 receptor availability
it was not a consistent finding, and, was not present in drug-naïve patients, although some
caveats remain.
Implications for the dopamine hypothesis of schizophrenia
Our findings provide in vivo evidence to support the dopamine hypothesis of schizophrenia.
Early versions of this hypothesis could only conjecture the nature of the abnormality.58 This
meta-analysis provides evidence to specify that the major dopaminergic abnormality in
schizophrenia is a presynaptic one, affecting dopamine synthesis capacity and release, and
that, in contrast, the overall effect on D2/3 receptor availability is small. This view is
supported by findings of elevated dopamine synthesis capacity in drug naïve individuals in
the prodrome to schizophrenia24, and of a further increase associated with the onset of the
psychotic disorder.59 There is also evidence of specificity as this presynaptic dopaminergic
dysfunction is not seen in non-psychotic affective and anxiety disorders (see review16).
Whilst we were unable to examine symptoms in our meta-analyses, the challenge studies
link elevated dopamine release to positive rather than negative symptoms.17, 36
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Whilst our findings support proposals that dopaminergic dysfunction is a final common
pathway to psychosis, they do not address the issue of what drives the presynaptic striatal
alterations. One candidate is decreased D1 mediated dopaminergic neurotransmission in the
frontal cortex (see review60 and61, 62). Another candidate, supported by preclinical models
and some human findings63-65, is glutamatergic dysfunction.
Our finding that dopamine transporter availability is unaltered indicates that there is no
elevation in transporter levels that might compensate for elevated dopamine release. It may
also explain the later age of onset of schizophrenia in women than men, as women tend to
have higher dopamine transporter availability than men, which naturally declines with age in
both sexes.66 Although our findings indicate that transporter availability is unaltered, it
remains possible that transporter function is altered in schizophrenia.
As we focussed on the striatum, it is not possible to know if our presynaptic findings are
specific to the striatum or also relevant to dopaminergic projections to other brain regions
and future work will need to evaluate the extra-striatal dopamine system. Our analyses of
striatal sub-regions suggest that the pre-synaptic elevation may be localised to the putamen.
However, these findings should be considered as exploratory as not all studies provided data
and the resolution of scanners varied markedly (see supplementary table 1). The putamen
localisation contrasts with recent findings focusing on functional, as opposed to purely
anatomical, sub-regions of the striatum, which have suggested that the dopaminergic
dysfunction is localised in a part of the caudate nucleus that is linked to associative cortical
regions.67, 68 Unfortunately, there were too few studies for the functional sub-regions to be
examined in our meta-analysis and studies using high resolution scanners are warranted to
examine sub-regional effects further.
Implications for treating schizophrenia
The current drug treatments for schizophrenia were discovered prior to notions of dopamine
as a neurotransmitter, or our ability to measure its function in vivo in humans. They were the
outcome of empiricism and serendipity, rather than rational drug design based on
pathophysiology. It has transpired that the major mode of action of all currently licensed
antipsychotic drugs is blockade of D2 receptors.9, 69 However, our meta-analysis indicates
that by blocking D2 receptors, current drugs are acting down-stream of the locus of the
largest dopaminergic abnormality in the disorder. Thus, whilst antipsychotics suppress
overall neurotransmission, they fail to target the major dopaminergic abnormality.
Furthermore, our finding that the D2/3 alterations were not present in drug-naïve patients
suggests that D2/3 receptor alterations are not intrinsic to the illness, but are secondary to
prior antipsychotic treatment. Although studies are needed to test this after accounting for
the factors discussed above, this interpretation is consistent with animal evidence that
antipsychotics result in D2/3 receptor up-regulation,70 and evidence that withdrawing
antipsychotic drugs in humans uncovers elevated D2/3 receptor availability.71 It is not
surprising then that when antipsychotics are stopped (usually by the patient) and there is
both nothing to suppress the dysregulated presynaptic dopaminergic system, and a
potentially supersensitive post-synaptic receptor system, there is a high risk of relapse.
Our findings indicate that rather than focussing exclusively on post-synaptic receptors,
future treatments should target the presynaptic control of dopamine synthesis and release.
Interestingly one of the first effective drug treatments for schizophrenia was reserpine,72 and
more recent data show that AMPT administration is associated with a rapid and profound
reduction in psychotic symptoms.36 As both these drugs deplete presynaptic dopamine
stores there is thus proof of principle that acting on the presynaptic dopaminergic system can
treat psychosis. However, whilst presynaptic dopamine depletion seems logical from a
pathophysiological perspective, it raises a technical challenge as dopamine and
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norepinephrine share part of the same synthetic pathway. Thus treatments that interfere with
dopamine also risk affecting norepinephrine synthesis leading to undesirable side-effects.
Therefore future efforts at presynaptic modulation will need to go beyond the simple
depletion of dopamine or blockade of its synthesis as the cost-benefit ratio of this is unlikely
to be therapeutically viable. They will also probably need to show some regional selectivity
if they are to avoid altering dopamine neurotransmission in the frontal cortex, and
potentially worsening negative symptoms and cognitive impairments, both of which have
been linked to frontal cortical D1 receptor availability in schizophrenia.42
Interestingly patients who respond less well to antipsychotic drugs have been found to show
lower synaptic dopamine levels36, and findings indicate treatment resistant patients show
normal dopamine synthesis capacity.73 These findings suggest that psychotic symptoms in
some patients may be unrelated to dopaminergic function, at least as indexed by these
imaging techniques.
Although we did not find a major alteration in dopamine transporter or D2/3 receptor
availability, there could nevertheless be other functional alterations. In fact, this is indirectly
suggested by findings that patients with schizophrenia are supersensitive to the
psychotogenic effects of the D2 receptor agonist apomorphine when given at high doses.74
Interestingly, when apomorphine is given at low doses, which are thought to have a
preferential presynaptic action to reduce dopaminergic transmission, it has an antipsychotic
effect.75 D2 receptors may exist in forms with differing affinities for dopamine, and it has
been proposed that there is an excess of the high affinity form in schizophrenia.74 However,
the first in vivo study in schizophrenia using a radiotracer selective for the high affinity form
found no evidence of alterations, although a significant caveat is that this radiotracer also
shows appreciable binding to D3 receptors.76 Notwithstanding this, other aspects of D2/3
receptor function, such as internalisation or signal transduction, or the function of other
dopamine receptors could be abnormal in schizophrenia and warrant investigation in
patients. If these or other aspects of D2 function are abnormal this would suggest new drug
targets, and, even if D2 function is unaltered, finding new ways to intervene at this level
could still be useful to counteract the effects of presynaptic dysfunction on dopamine
neurotransmission.
An attractive feature of the current findings is that the pathophysiological target – increased
dopamine synthesis capacity and dopamine release – can now be measured in preclinical
models and humans using exactly the same molecular imaging techniques, as has been done
for dopamine transporters and D2/3 receptors77. So, whilst most of the animal models used
to develop antipsychotics in the past have had to rely on indirect measures (such as
amphetamine-induced locomotion, or conditioned avoidance response abolition), the current
findings provide a pathophysiological target that can be directly measured in animals. With
advances in small animal imaging and experimental human studies it should be possible to
induce the precise presynaptic abnormality in animal models, and to measure the response to
new medications in animals and in experimental human models in the same way.
Conclusions
There is consistent evidence of presynaptic dysfunction in schizophrenia with a large effect
size, but no evidence of a compensatory increase in dopamine transporter availability to
buffer the system. D2/3 receptor up-regulation is small and not detected in antipsychotic
naïve patients. These findings suggest that drug development should target the presynaptic
regulation of dopamine synthesis and release.
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Figure 1.
Studies of presynaptic dopaminergic function: Forrest plot showing the effect size and 95%
confidence intervals of the difference between patients with schizophrenia and controls by
study. There was evidence of a significant elevation in schizophrenia with a summary effect
size of d=0.79.
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Figure 2.
Studies of presynaptic dopaminergic function: the effect sizes for studies by antipsychotic
treatment history (in the boxplot the band is the median and the whiskers indicate the lowest
and highest data points that are within 1.5 * the interquartile range, and data outside this
range (circles if present) are regarded as potential outliers)
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Figure 3.
Studies of dopamine transporter availability: Forrest plot showing the effect size and 95%
confidence intervals of the effect sizes by study. The 95% confidence interval for the
summary effect size (lozenge, d=0.34) includes 0, indicating no significant difference
between patients with schizophrenia and controls.
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Figure 4.
Studies of D2/3 receptor availability: Forrest plot showing the effect size and 95%
confidence intervals of the effect sizes by study. There was evidence of a small increase in
D2 receptor availability in schizophrenia with a summary effect size (lozenge) of d=0.26.
Howes et al. Page 18
Arch Gen Psychiatry. Author manuscript; available in PMC 2013 August 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 5.
Schematic diagram summarising the findings from our meta-analyses of dopamine imaging
findings in schizophrenia showing that the major abnormality is increased presynaptic
dopamine synthesis capacity and release (not shown to scale).
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